☆ 4.4 Letter

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

HAEMATOLOGICA (2021)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 106, Issue 8, Pages 2277-2280

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2021.278301

Keywords

-

Categories

Hematology

Funding

  1. Takeda Pharmaceuticals Co, Ltd.
  2. Korean Health Technology R&D Project Strategic Center of Cell and Bio Therapy for Heart, Diabetes & Cancer through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health Welfare (MHW) [HI-17C-2085]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.